Inotiv (NOTV) Stock
Small drug testing firm serving biotech and pharmaceutical clients. Here's the price, business snapshot, and what's worth knowing about Inotiv in October 2026.
INOTIV Inc (NOTV) is a small-cap contract research organisation that provides preclinical safety, toxicology and bioanalytical services to pharmaceutical and biotechnology clients. With a market capitalisation around $46 million, the company operates in a sector that benefits from drug developers outsourcing complex and regulated testing. Investors should know INOTIV’s revenue depends on client R&D budgets, the timing of project work and regulatory approvals — factors that can cause uneven quarterly results. Potential upside includes steady demand for preclinical services and consolidation in the CRO industry; downside risks include small‑cap liquidity constraints, competition from larger CROs, and sensitivity to biotech funding cycles. This description is educational and not investment advice; performance can vary and investors should review the company’s latest filings, financials and risk disclosures before making decisions.
Inotiv (NOTV) Stock Forecast
Analyst price target, next 12 months
$6.67
+8243.8% vs today's $0.08
Price range over the last 12 months
Close to its 12-month low
Analysts covering Inotiv have a consensus 12-month target of $6.67, above the current price of $0.08.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying INOTIV's stock with a target price of $6.67, indicating strong potential growth.
Financial Health
Inotiv Inc shows moderate revenue and cash flow, but profitability could be improved.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Outsourcing trend tailwind
Pharma and biotech increasingly outsource preclinical testing, which can support demand for INOTIV’s services, though revenue can be uneven by quarter.
Industry positioning matters
A focused CRO can win niche work and partnerships, but competition from larger global players and consolidation are ongoing challenges.
Small-cap considerations
Smaller market cap means potential for higher returns but also greater volatility and liquidity risk; review financials and risk disclosures carefully.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.